I’m joking, kids! Nothing is falling faster than Covid vaccine effectiveness.
And unlike vaccine effectiveness, Moderna stock has a zero lower bound.
Still, these charts are stunning. Given that Moderna has close to $20 billion in vaccine sales baked in for 2022, a market cap of $58 billion suggests investors are moving closer and closer to assigning ZERO value to its mRNA technology going forward.
Sounds about right.
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.